Skip to Content
Søg Menu

Flere behandlingsmuligheter nå enn før for HER2-lav brystkreft

Det er en spennende tid fremover for behandling av HER-2 lav brystkreft, sier Bjørn Naume, professor ved Oslo Universitetssykehus, overlege og leder for Norsk brystkreftgruppe. Han understreker at nye og kommende behandlingsmuligheter gir en vesentlig og viktig mulighet for pasientene våre til bedre kontroll på sykdommen over lengre tid ved metastaser.
Bjørn Naume

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Nordic Collaboration on Breast Cancer Research Reignited

/ BestPractice Nordic
Brystcancer
Louise Wichmann Matthiessen

Nye positive resultater for behandling af brystcancer fremlagt på ESMO 2024

/ Louise Wichmann Matthiessen
ESMO24Brystcancer Play the Video 03:02
Peter Schmid

Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

/ Peter Schmid
ESMO24Brystcancer Play the Video 04:50
Bjørn Naume

Nye behandlingstilbud for HER2-lav brystkreft

/ Bjørn Naume
Brystcancer Play the Video 07:08
Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
ESMO24Brystcancer Play the Video 4:51
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
ESMO24Brystcancer Play the Video 1:23

New Data on Trastuzumab Deruxtecan Shows Promising Outcomes in HER2-Positive Metastatic Breast Cancer with Brain Metastases: Results from DESTINY-Breast12

/ Jan Andreasen
ESMO24Brystcancer

ESMO24: Breastfeeding After Breast Cancer Treatment Is Safe

/ Sofie Pohl
ESMO24Brystcancer
Frederik Baastrup

Implementering af AI i screening for brystkræft

/ Frederik Baastrup
AIDSKO24Brystcancer Play the Video 4:57
Back to top